Toll Free: 1-888-928-9744

Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Pipeline Review, H2 2017

Published: Aug 8, 2017 | Pages: 66 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Pipeline Review, H2 2017, provides an overview of the Granulomatosis with Polyangiitis (Wegener Polyangiitis) (Immunology) pipeline landscape.

Wegener Polyangiitis is an uncommon disorder that causes inflammation of blood vessels. This inflammation restricts blood flow to various organs. Signs and symptoms include constantly runny nose, nose bleeds, ear infections, cough, chest pain, skin sores and fever. Predisposing factor includes age. Treatment includes immunosuppressive and corticosteroids. 

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Granulomatosis with Polyangiitis (Wegener Polyangiitis) (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Granulomatosis with Polyangiitis (Wegener Polyangiitis) (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Granulomatosis with Polyangiitis (Wegener Polyangiitis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase I, Preclinical and Unknown stages are 1, 3, 1, 4 and 2 respectively.

Granulomatosis with Polyangiitis (Wegener Polyangiitis) (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Granulomatosis with Polyangiitis (Wegener Polyangiitis) (Immunology).
- The pipeline guide reviews pipeline therapeutics for Granulomatosis with Polyangiitis (Wegener Polyangiitis) (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Granulomatosis with Polyangiitis (Wegener Polyangiitis) (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Granulomatosis with Polyangiitis (Wegener Polyangiitis) (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Granulomatosis with Polyangiitis (Wegener Polyangiitis) (Immunology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Granulomatosis with Polyangiitis (Wegener Polyangiitis) (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Granulomatosis with Polyangiitis (Wegener Polyangiitis) (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Overview Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Therapeutics Development Pipeline Overview Pipeline by Companies Products under Development by Companies Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Companies Involved in Therapeutics Development Bionovis SA Bristol-Myers Squibb Company Celltrion Inc ChemoCentryx Inc Coherus BioSciences Inc Kyowa Hakko Kirin Co Ltd Sandoz International GmbH TTY Biopharm Company Ltd Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Drug Profiles abatacept - Drug Profile Product Description Mechanism Of Action R&D Progress avacopan - Drug Profile Product Description Mechanism Of Action R&D Progress benralizumab - Drug Profile Product Description Mechanism Of Action R&D Progress rituximab biosimilar - Drug Profile Product Description Mechanism Of Action R&D Progress rituximab biosimilar - Drug Profile Product Description Mechanism Of Action R&D Progress rituximab biosimilar - Drug Profile Product Description Mechanism Of Action R&D Progress rituximab biosimilar - Drug Profile Product Description Mechanism Of Action R&D Progress rituximab biosimilar - Drug Profile Product Description Mechanism Of Action R&D Progress rituximab biosimilar - Drug Profile Product Description Mechanism Of Action R&D Progress rituximab biosimilar - Drug Profile Product Description Mechanism Of Action R&D Progress rituximab biosimilar - Drug Profile Product Description Mechanism Of Action R&D Progress Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Dormant Projects Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Discontinued Products Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Product Development Milestones Featured News & Press Releases Jun 29, 2017: Celltrion and Teva Announce U.S. FDA Acceptance of Biologics License Application for Proposed Biosimilar to Rituxan (rituximab) Jun 19, 2017: Sandoz receives approval in Europe for Rixathon (biosimilar rituximab) to treat blood cancers and immunological diseases May 18, 2017: Celltrion Healthcare Hungary Receives CHMP Positive Opinion for Blitzima (rituximab) Apr 21, 2017: Sandoz Receives CHMP Positive Opinion For Rixathon (rituximab) Dec 15, 2016: Celltrion Healthcare Hungary Receives CHMP Positive Opinion for Truxima Dec 04, 2014: ChemoCentryx Granted EU Orphan Drug Designation for CCX168, an Orally Administered Complement C5a Receptor Inhibitor, for the Treatment of Microscopic Polyangiitis and Granulomatosis With Polyangiitis, Two Forms of ANCA-Associated Vasculitis Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Granulomatosis with Polyangiitis (Wegener Polyangiitis), H2 2017 Number of Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Pipeline by Bionovis SA, H2 2017 Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Pipeline by Bristol-Myers Squibb Company, H2 2017 Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Pipeline by Celltrion Inc, H2 2017 Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Pipeline by ChemoCentryx Inc, H2 2017 Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Pipeline by Coherus BioSciences Inc, H2 2017 Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2017 Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Pipeline by Sandoz International GmbH, H2 2017 Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Pipeline by TTY Biopharm Company Ltd, H2 2017 Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Dormant Projects, H2 2017 Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Discontinued Products, H2 2017


List of Figures
Number of Products under Development for Granulomatosis with Polyangiitis (Wegener Polyangiitis), H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products by Targets, H2 2017 Number of Products by Stage and Targets, H2 2017 Number of Products by Mechanism of Actions, H2 2017 Number of Products by Stage and Mechanism of Actions, H2 2017 Number of Products by Routes of Administration, H2 2017 Number of Products by Stage and Routes of Administration, H2 2017 Number of Products by Molecule Types, H2 2017 Number of Products by Stage and Molecule Types, H2 2017

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global fingerprint access control systems market size is estimated to reach USD 4.4 billion by 2022, as per a new research report by Radiant Insights, Inc. Growing safety and security concerns of individual as well as organization is projected to dri

Read More...

Global thermoplastic polyurethane (TPU) films market size is likely to be valued at USD 724.6 million by 2020; as per a new research report by Radiant Insights, Inc. Increase in lightweight plastics demand in order to achieve vehicle fuel efficiency

Read More...

Global commercial drone market size is estimated to reach USD 2,069.6 million by 2022, as per a new research report by Radiant Insights, Inc. Increasing application of these machines in various industry sectors such as military, agriculture and energ

Read More...

Global Automated Test Equipment (ATE) market is expected to be valued at USD 4.48 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing design complexity coupled with need for effective testing is expected to drive the gl

Read More...

Global activated carbon market size is likely to be valued at USD 5.3 billion by 2020; as per a new research report by Radiant Insights, Inc. Increase in commercial & residential waste water treatment demand owing to escalation in water prices is ant

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify